219 related articles for article (PubMed ID: 32970737)
1. A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer.
Miyamoto Y; Schirripa M; Suenaga M; Cao S; Zhang W; Okazaki S; Berger MD; Matsusaka S; Yang D; Ning Y; Baba H; Loupakis F; Lonardi S; Pietrantonio F; Borelli B; Cremolini C; Yamaguchi T; Lenz HJ
PLoS One; 2020; 15(9):e0239439. PubMed ID: 32970737
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Murgioni S; Rossini D; Marmorino F; Mennitto A; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Loupakis F; Lenz HJ
Ann Oncol; 2017 May; 28(5):1015-1022. PubMed ID: 28453695
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
4. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Tsuji A; Tsuchihashi K; Sakai D; Ueno H; Tamura T; Yamashita K; Shimada Y
Int J Clin Oncol; 2020 Apr; 25(4):614-621. PubMed ID: 31838590
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Zhang Q; Wang Q; Wang X; Li J; Shen L; Peng Z
Int J Colorectal Dis; 2020 Feb; 35(2):295-306. PubMed ID: 31848739
[TBL] [Abstract][Full Text] [Related]
6. Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Ning Y; Cremolini C; Antoniotti C; Borelli B; Mashima T; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Lonardi S; Yamaguchi T; Falcone A; Loupakis F; Lenz HJ
Clin Colorectal Cancer; 2018 Jun; 17(2):e395-e414. PubMed ID: 29606345
[TBL] [Abstract][Full Text] [Related]
7. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
Sonbol MB; Benkhadra R; Wang Z; Firwana B; Walden DJ; Mody K; Hubbard JM; Murad MH; Ahn DH; Bekaii-Saab T
Oncologist; 2019 Sep; 24(9):1174-1179. PubMed ID: 31164455
[TBL] [Abstract][Full Text] [Related]
8. 3'-Deoxy-3'-
Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
[TBL] [Abstract][Full Text] [Related]
9. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Dadduzio V; Salvatore L; Borelli B; Pietrantonio F; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Loupakis F; Lenz HJ
Eur J Cancer; 2017 Nov; 86():197-206. PubMed ID: 28992563
[TBL] [Abstract][Full Text] [Related]
10. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
[TBL] [Abstract][Full Text] [Related]
11. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy.
Angeles A; Hung W; Cheung WY
Med Oncol; 2018 Jun; 35(8):114. PubMed ID: 29936654
[TBL] [Abstract][Full Text] [Related]
12. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
13. Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer.
Miyamoto Y; Hiyoshi Y; Akiyama T; Kiyozumi Y; Eto K; Yohei N; Iwagami S; Baba Y; Yoshida N; Baba H
Digestion; 2019; 99(1):79-85. PubMed ID: 30554226
[TBL] [Abstract][Full Text] [Related]
14. Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis.
Casadei-Gardini A; Vagheggini A; Gelsomino F; Spallanzani A; Ulivi P; Orsi G; Rovesti G; Andrikou K; Tamburini E; Scartozzi M; Cascinu S
Clin Colorectal Cancer; 2020 Jun; 19(2):82-90.e9. PubMed ID: 32192883
[TBL] [Abstract][Full Text] [Related]
15. The prognostic role of polypharmacy in metastatic colorectal cancer patients treated with regorafenib.
Yekedüz E; Aktaş EG; Köksoy EB; Doğan N; Ürün Y; Utkan G
Future Oncol; 2022 Mar; 18(9):1067-1076. PubMed ID: 35109668
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study.
Kim JH; Kim SY; Kim KP; Kim TW; Chae SY; Kim HJ; Kim JS; Ryu JS; Moon DH; Kim JE; Hong YS
Target Oncol; 2019 Dec; 14(6):689-697. PubMed ID: 31555963
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis.
Abrahao ABK; Ko YJ; Berry S; Chan KKW
Clin Colorectal Cancer; 2018 Jun; 17(2):113-120. PubMed ID: 29174481
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.
Røed Skårderud M; Polk A; Kjeldgaard Vistisen K; Larsen FO; Nielsen DL
Cancer Treat Rev; 2018 Jan; 62():61-73. PubMed ID: 29175677
[TBL] [Abstract][Full Text] [Related]
20. The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong.
Lam KO; Lee KC; Chiu J; Lee VH; Leung R; Choy TS; Yau T
Postgrad Med J; 2017 Jul; 93(1101):395-400. PubMed ID: 27836933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
